Otsuka Pharmaceuticals and Bristol Myers-Squibb are seeking to withdraw admissions in patent litigation against Generic Health over anti-psychotic drug Abilify, following a landmark ruling last year against Wyeth that clarified the issue of compensation under the usual undertaking for damages in pharmaceutical patent cases.
Ashley & Martin signed up 25,000 customers to its hair loss program on contracts that put them on the hook for paying for treatment they didn’t receive, a judge has found.
A mortgage broker has successfully opposed REA Group’s application to trade mark “realestate.com.au Home Loans”, with a delegate finding the mark is not adapted to distinguish REA’s online services.
Merck Sharp & Dohme has emerged victorious in a battle over documents with Wyeth, as the parties gear up for a hearing on Wyeth’s request to reopen a trial over three patents for its Prevnar 13 pneumococcal vaccine.
A judge has removed the funder and law firm leading the Banksia Securities class action from their roles supervising a proposed settlement distribution scheme after the funder was accused of intimidation, a lack of experience and charging excessive costs.
Biotech company Cryosite has agreed to a $1 million settlement for losses resulting from legal advice received in relation to a merger agreement that left the company facing $1.05 million in penalties for engaging in cartel conduct.
Six individuals interviewed by ASIC in relation to the collapse of sandalwood producer Quintis have sought leave to intervene in the regulator’s case against the company’s founder, Frank Wilson, after he sought discovery from ASIC of interview transcripts.
Global pharmaceutical firm Pfizer is mulling an application to stay a lawsuit by Merck Sharp & Dohme seeking to invalidate a patent related to the blockbuster Prevnar 13 vaccine as it awaits the outcome of similar proceedings in the US.
A contempt of court prosecution ordered against Google for failing to immediately remove allegedly defamatory online reviews has been thrown out, with a judge saying the internet giant did not act in reckless or negligent disregard of the court’s removal orders.
AFT Pharmaceuticals has challenged a Federal Court decision that found its Maxisegic ads were misleading and deceptive, saying the judge “set the bar too high” by requiring it to prove there was an adequate scientific foundation for its painkiller representations.